Immunogenicity comparison between codon optimized HIV-1 CRF BC_07 gp140 and gp145 vaccines

AIDS Research and Human Retroviruses

Volumn 23, Issue 11, 2007, Pages 1396-1404

  Liu, Lianxing ^a,b,c   Wan, Yanmin ^b   Xu, Jianqing ^b   Huang, Xianggang ^b   Wu, Lan ^b,d   Liu, Yong ^b   Shao, Yiming ^a,b  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN 140; GLYCOPROTEIN 145; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; DNA VACCINE; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; ENVELOPE GENE; FEMALE; GENE SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; GENETICS; IMMUNOLOGY; SERODIAGNOSIS; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; CODON; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV-1; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PLASMIDS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 38449096709     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0131     Document Type: Article

References (44)

1. Essex M: Human immunodeficiency viruses in the developing world. Adv Virus Res 1999;53:71-88.
2. Esparza J and Bhamarapravati N: Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how? Lancet 2000;355:2061-2066.
3. Osmanov S, Pattou C, Walker N, Schwardlander B, and Esparza J: Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002;29:184-190.
4. Shankar SK, Mahadevan A, Satishchandra P, et al.: Neuropathology of HIV/AIDS with an overview of the Indian scene. Indian J Med Res 2005;121:468-488.
5. Cole KS, Rowles JL, Jagerski BA, et al.: Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol 1997;71:5069-5079.
6. Cole KS, Paliotti MJ, Murphey-Corb M, and Montelaro RC: Maturation of envelope-specific antibody responses to linear determinants in monkeys inoculated with attenuated SIV. J Med Primatol 2000;29:220-230.
7. Letvin NL, Barouch DH, and Montefiori DC: Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 2002;20:73-99.
8. Mascola JR: Defining the protective antibody response for HIV-1. Curr Mol Med 2003;3:209-216.
9. Amara RR, Villinger F, Staprans SI, et al.: Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002;76:7625-7631.
10. Letvin NL, Huang Y, Chakrabarti BK, et al.: Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004;78:7490-7497.
11. Belshe RB, Gorse GJ, Mulligan MJ, et al.: Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998;12:2407-2415.
12. Belshe RB, Graham BS, Keefer MC, et al.: Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA 1994;272:475-480.
13. Graham BS, McElrath MJ, Connor RI, et al.: Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis 1998;177:310-319.
14. Mascola JR, Snyder SW, Weislow OS, et al.: Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996;173:340-348.
15. Matthews TJ: Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses 1994;10:631-632.
16. Beddows S, Lister S, Cheingsong R, Bruck C, and Weber J: Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J Virol 1999;73:1740-1745.
17. VanCott TC, Bethke FR, Burke DS, Redfield RR, and Birx DL: Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol 1995;155:4100-4110.
18. Evans LA, Thomson-Honnebier G, Steimer K, et al.: Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV. AIDS 1989;3:273-276.
19. Gnann JW Jr, Nelson JA, and Oldstone MB: Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol 1987;61:2639-2641.
20. Chakrabarti BK, Kong WP, Wu BY, et al.: Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002;76:5357-5368.
21. Yang X, Farzan M, Wyatt R, and Sodroski J: Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 2000;74:5716-5725.
22. Sanders RW, Vesanen M, Schuelke N, et al.: Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002;76:8875-8889.
23. Bower JF, Yang X, Sodroski J, and Ross TM: Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 2004;78:4710-4719.
24. Beddows S, Schulke N, Kirschner M, et al.: Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005;79:8812-8827.
25. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, and Sodroski J: Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002;76:4634-4642.
26. Bower JF, Li Y, Wyatt R, and Ross TM: HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies. Vaccine 2006;24:5442-5451.
27. Earl PL, Sugiura W, Montefiori DC, et al.: Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 2001;75:645-653.
28. Wan Y, Wu L, Liu L, et al.: Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Vaccine 2007;25:4949-4959.
29. Goulder PJ, Brander C, Annamalai K, et al.: Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J Virol 2000;74:5679-5690.
30. Binley J and Moore JP: HIV-cell fusion. The viral mousetrap. Nature 1997;387:346-348.
31. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman D, and Nunberg JH: Fusion-competent vaccines: Broad neutralization of primary isolates of HIV. Science 1999;283:357-362.
32. Moore JP, Sattentau QJ, Wyatt R, and Sodroski J: Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol 1994;68:469-484.
33. Moore JP, Willey RL, Lewis GK, Robinson J, and Sodroski J: Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J Virol 1994;68:6836-6847.
34. Nakamura GR, Byrn R, Rosenthal K, et al.: Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates. AIDS Res Hum Retroviruses 1992;8:1875-1885.
35. Zwick MB, Parren PW, Saphire EO, et al.: Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol 2003;77:5863-5876.
36. Moore JP and Sodroski J: Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996;70:1863-1872.
37. Bongertz V, Costa CI, Veloso VG, et al.: Vertical HIV-1 transmission: Importance of neutralizing antibody titer and specificity. Scand J Immunol 2001;53:302-309.
38. Kang CY, Hariharan K, Nara PL, Sodroski J, and Moore JP: Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J Virol 1994;68:5854-5862.
39. Gorny MK, Revesz K, Williams C, et al.: The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol 2004;78:2394-2404.
40. Spear GT, Takefman DM, Sharpe S, Ghassemi M, and Zolla-Pazner S: Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Virology 1994;204:609-615.
41. Laman JD, Schellekens MM, Abacioglu YH, et al.: Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. J Virol 1992;66:1823-1831.
42. Buchacher A, Predl R, Strutzenberger K, et al.: Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994;10:359-369.
43. Benjouad A, Gluckman JC, Montagnier L, and Bahraoui E: Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160. J Virol 1993;67:1693-1697.
44. Skinner MA, Ting R, Langlois AJ, et al.: Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res Hum Retroviruses 1988;4:187-197.